Key facts
- This page summarizes Robert Michael Dudley's Form 4 filing for Transcode Therapeutics, Inc. (RNAZ).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 22 Jun 2023, 18:23.
Robert Michael Dudley - 20 Jun 2023 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- RNAZ
- Reported as of
- 20 Jun 2023
- Net transaction value
- +$48,665
- SEC form
- 4
- Accepted by SEC
- 22 Jun 2023, 18:23:24 UTC
- Prior SEC filing
- 14 Jun 2023
- Next SEC filing
- 02 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas A. Fitzgerald, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Michael Dudley filed Form 4 for Transcode Therapeutics, Inc. (RNAZ) on 22 Jun 2023.
Change
- Previous filing in this sequence was filed on 14 Jun 2023.
- Current net transaction value: +$48,665.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RNAZ
transaction
Common Stock
Purchase
- Transaction value
- $16,847
- Shares
- +6,607
- Change %
- +10%
- Price
- $2.55
- Shares after
- 70,262
- Date
- 20 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
RNAZ
transaction
Common Stock
Purchase
- Transaction value
- $31,818
- Shares
- +12,000
- Change %
- +17%
- Price
- $2.65
- Shares after
- 82,262
- Date
- 21 Jun 2023
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.54 to $2.55. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.
Footnote F2
Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.60 to $2.70. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.